Justin Morris Honce

Justin Morris Honce

Auto-generated profile, based on publicly available information

Justin Morris Honce

Department of Radiology, University of Colorado Anschutz Medical Campus, 19th Ave. Mail Stop C278, Aurora, CO, 80045, United States, 1 303-724-3796, 1 303-724-3795

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Complementary Therapies in Medicine
Verified
Journal Article
Closed access
JKJohn H. Kindred
John H. Kindred
KLKaigang Li
Kaigang Li
NKNathaniel B. Ketelhut
Nathaniel B. Ketelhut
FPFelix Proessl
Felix Proessl
Brett W FlingBrett W Fling
Brett W Fling
TRThorsten Rudroff
Thorsten Rudroff

12 February 2019 in Neurology
Verified
Journal Article
Closed access
PDF file
JHJustin M. Honce
Justin M. Honce
KNKavita V. Nair
Kavita V. Nair
SSStefan Sillau
Stefan Sillau
BVBrooke Valdez
Brooke Valdez
AMAugusto Miravalle
Augusto Miravalle
TVTimothy Vollmer
Timothy Vollmer
Objective To examine whether rituximab induction followed by glatiramer acetate (GA) monotherapy is more effective than GA alone for the treatment of relapsing multiple sclerosis with active disease. Methods This was a single-center, double-blind, placebo-controlled study. Fifty-five participants were randomly assigned (1:1 ratio) to either rituximab (R-GA) or placebo (P-GA) induction, followed by GA therapy initiated in all participants. Participants were followed up to 3 years. The primary endpoint was the number of participants with no evidence of disease activity (NEDA): those without relapse, new MRI lesions, and sustained change in disability. Results Twenty-eight and 27 participants received rituximab and placebo induction, respectively, with one participant in each arm withdrawing before 6-month MRI. There were no significant differences in baseline characteristics. At end of study, 44.44% of R-GA participants demonstrated NEDA vs 19.23% of P-GA participants (p = 0.049). Treatment failed for a smaller proportion of R-GA participants (37.04% R-GA vs 69.23% P-GA, p = 0.019), and time to treatment failure was longer (23.32 months R-GA vs 11.29 months P-GA, p = 0.027). Fewer participants in the R-GA arm had new lesions (25.93% R-GA vs 61.54% P-GA, p = 0.009), and there were fewer new T2 lesions (0.48 R-GA vs 1.96 P-GA, p = 0.027). Probability of demonstrating NEDA in the R-GA arm returned to baseline within the study period. There were no differences in adverse events. Conclusions Induction therapy with rituximab followed by GA may provide superior efficacy in the short term than GA alone in relapsing multiple sclerosis, but this benefit appears to wane within the study period. Larger studies are needed to assess sustainability of results. ClinicalTrials.gov identifier NCT01569451.

1 May 2015 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
ENEric M. Nyberg
Eric M. Nyberg
JTJody Tanabe
Jody Tanabe
JHJustin M. Honce
Justin M. Honce
TKTheodore Krmpotich
Theodore Krmpotich
ESErika Shelton
Erika Shelton
BBBrian D. Berman
Brian D. Berman

25 June 2013 in Multiple Sclerosis International
Verified
Journal Article
Open access
PDF file
JHJustin Morris Honce
Justin Morris Honce
It is abundantly clear that there is extensive gray matter pathology occurring in multiple sclerosis. While attention to gray matter pathology was initially limited to studies of autopsy specimens and biopsies, the development of new MRI techniques has allowed assessment of gray matter pathologyin vivo. Current MRI techniques allow the direct visualization of gray matter demyelinating lesions, the quantification of diffuse damage to normal appearing gray matter, and the direct measurement of gray matter atrophy. Gray matter demyelination (both focal and diffuse) and gray matter atrophy are found in the very earliest stages of multiple sclerosis and are progressive over time. Accumulation of gray matter damage has substantial impact on the lives of multiple sclerosis patients; a growing body of the literature demonstrates correlations between gray matter pathology and various measures of both clinical disability and cognitive impairment. The effect of disease modifying therapies on the rate accumulation of gray matter pathology in MS has been investigated. This review focuses on the neuroimaging of gray matter pathology in MS, the effect of the accumulation of gray matter pathology on clinical and cognitive disability, and the effect of disease-modifying agents on various measures of gray matter damage.

21 September 2015 in Multiple Sclerosis International
Verified
Journal Article
Open access
PDF file
JHJustin M. Honce
Justin M. Honce
LNLidia Nagae
Lidia Nagae
ENEric Nyberg
Eric Nyberg
Natalizumab (Tysabri) is a monoclonal antibody (α4 integrin antagonist) approved for treatment of multiple sclerosis, both for patients who fail therapy with other disease modifying agents and for patients with aggressive disease. Natalizumab is highly effective, resulting in significant decreases in rates of both relapse and disability accumulation, as well as marked decrease in MRI evidence of disease activity. As such, utilization of natalizumab is increasing, and the presentation of its associated complications is increasing accordingly. This review focuses on the clinical and neuroimaging features of the major complications associated with natalizumab therapy, focusing on the rare but devastating progressive multifocal leukoencephalopathy (PML). Associated entities including PML associated immune reconstitution inflammatory syndrome (PML-IRIS) and the emerging phenomenon of rebound of MS disease activity after natalizumab discontinuation are also discussed. Early recognition of neuroimaging features associated with these processes is critical in order to facilitate prompt diagnosis, treatment, and/or modification of therapies to improve patient outcomes.

1 May 2016 in Physical Medicine and Rehabilitation Clinics of North America
Verified
Journal Article
Closed access
JHJustin M. Honce
Justin M. Honce
ENEric Nyberg
Eric Nyberg
IJIsaac Jones
Isaac Jones
LNLidia Nagae
Lidia Nagae